Le Lézard
Classified in: Health, Covid-19 virus
Subject: SVY

Changes to Approvals & Regulations of Medical Devices due to COVID-19


DUBLIN, July 10, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the medical devices industry "Medical Devices and COVID-19 - Changes to the Approval Process"

Research and Markets Logo

Medical device manufacturers have concentrated their resources on devices to fight the COVID-19 pandemic. There has also been less demand for other medical devices due to a lower number of non COVID-19 related procedures being carried out. As a result some manufacturers have seen lower demand for their other medical devices and have temporarily closed production facilities and furloughed staff. Analysts expect that the impact of COVID-19 on the medical device industry could lead to greater demand for reshoring of device production and an increased focus on diagnostic devices. 

In order to avoid shortages of vital medical equipment, approval bodies in the US and European Union have granted priority review and delayed reporting requirements. In the US, the FDA has issued Emergency Use Authorizations for certain devices. The EUA designation provides expedited access to the US healthcare market but only lasts as long as the public health emergency for which they were granted. Similarly, the EU has postponed the Medical Device Regulation reporting deadline by one year. This regulation requires manufacturers to conduct post market studies to ensure the continued safety of their products.

To see the full article and a list of related reports on the market, visit "Medical Devices and COVID-19 - Changes to the Approval Process"

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...

at 08:00
Citius Pharmaceuticals Inc. ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...

at 08:00
Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami, sponsored by PrecisCa and the Community Oncology Alliance...

at 08:00
Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation at two prestigious medical conferences: the American...



News published on and distributed by: